Visualization Versus Intraoperative Neuromonitoring of the Recurrent Laryngeal Nerves During Thoracoscopic Esophagectomy

Sponsor
Tianjin Medical University Cancer Institute and Hospital (Other)
Overall Status
Recruiting
CT.gov ID
NCT05199168
Collaborator
(none)
120
1
2
28
4.3

Study Details

Study Description

Brief Summary

The clinical value of intraoperative nerve monitoring (IONM) in thoracoscopic esophagectomy remains uncertain. The aim of this randomized clinical trial was to compare the impact of RLN visualization versus IONM on their morbidity following thoracoscopic esophagectomy.

Condition or Disease Intervention/Treatment Phase
  • Procedure: intraoperative nerve monitoring
N/A

Detailed Description

Recurrent laryngeal nerves (RLN) lymph nodes are the most common metastatic areas in esophageal squamous carcinoma. It is a clinical challenge to reduce high incidence of RLN injury rate result from routine dissection of RLN lymph nodes. Thoracoscopic approach may provide a clear operative field and potentially less invasive surgery. But there are still high RLN injury rate only depending on visualization of thoracoscopy. The use of intraoperative nerve monitoring (IONM) was shown very helpful to identify the RLN and associated with a reduction of RLN injury rate in thyroidectomy. However, there is no solid clinical evidence about the effectiveness of utility of IONM in thoracoscopic esophagectomy. Thus, the aim of this randomized clinical trial was to compare the impact of RLN visualization versus IONM on their morbidity following thoracoscopic esophagectomy.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
120 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Single (Participant)
Primary Purpose:
Treatment
Official Title:
Randomized Clinical Trial of Visualization Versus Intraoperative Neuromonitoring of the Recurrent Laryngeal Nerves During Thoracoscopic Esophagectomy
Actual Study Start Date :
Mar 1, 2022
Anticipated Primary Completion Date :
Feb 1, 2024
Anticipated Study Completion Date :
Jul 1, 2024

Arms and Interventions

Arm Intervention/Treatment
No Intervention: Thoracoscopic esophagectomy without IONM

Experimental: Thoracoscopic esophagectomy with IONM

Intraoperative bilateral recurrent laryngeal nerve monitoring was utilized during dissection of right and left recurrent laryngeal nerve lymph nodes.

Procedure: intraoperative nerve monitoring
Intraoperative bilateral recurrent laryngeal nerve monitoring was utilized during dissection of right and left recurrent laryngeal nerve lymph nodes.

Outcome Measures

Primary Outcome Measures

  1. Incidence of the recurrent laryngeal nerve injury [Till 6 months postoperatively]

    The vocal cord function will be assessed by an experienced otolaryngologist using a laryngoscope on 1st postoperative day.RLN palsy will be classified according to the following variables: site (unilateral versus bilateral); duration (temporary [i.e., recovering within 6 months] versus permanent [i.e. not recovering within 6 months])postoperatively.

Secondary Outcome Measures

  1. Number of nodes removed along the right and left RLN [The pathological analysis will be finished within 2 weeks.]

    number of lymph node removed

  2. Value of IONM during operation [1 Day of surgery]

  3. Post esophagectomy pneumonia rate [Duration of hospital stay, an expected average of 2~3 weeks.]

  4. Operation time (thoracic phase) [Intraoperative]

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 75 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  1. Histologically proven primary intrathoracic middle and lower esophageal squamous cell carcinoma and will undergo McKeown MIE and bilateral RLN lymph ndoe dissection.

  2. No superclavicular lymph node metastasis after preoperative examination.

  3. No contraindication for esophagectomy.

  4. Expected surgical R0 resection.

Exclusion Criteria:
  1. Pre-existed vocal cord dysfunction.

  2. Thorax pleural adhesion rendering minimal invasive approach unfeasible.

  3. Gastric tube cannot be used for reconstruction.

  4. Combined with hemorrhagic disease.

  5. Psychiatric patients.

  6. Inability to undergo curative resection and/or follow-up.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Department of minimally invasive esophageal surgery, Tianjin Medical University Cancer Institute and Hospital Tianjin Tianjin China 300060

Sponsors and Collaborators

  • Tianjin Medical University Cancer Institute and Hospital

Investigators

  • Principal Investigator: Hongjing Jiang, MD. Ph.D., Tianjin Medical University Cancer Institute and Hospital

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Tianjin Medical University Cancer Institute and Hospital
ClinicalTrials.gov Identifier:
NCT05199168
Other Study ID Numbers:
  • E20210023
First Posted:
Jan 20, 2022
Last Update Posted:
Jun 1, 2022
Last Verified:
Jan 1, 2022
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Tianjin Medical University Cancer Institute and Hospital
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jun 1, 2022